Zachary Hornby

Zachary D.
Hornby currently works at Novome Biotechnologies, Inc., as Director from 2021, Independa, Inc., as Director, Radionetics Oncology, Inc., as Director, Ignyta Operating, Inc., as Chief Operating Officer from 2014, and City Hill Ventures LLC, as Operating Partner.
Mr. Hornby also formerly worked at Boundless Bio, Inc., as President, Chief Executive Officer & Director from 2019 to 2026, Fate Therapeutics, Inc., as Senior Director-Business Development from 2010 to 2012, Halozyme Therapeutics, Inc., as Director-Business Development from 2008 to 2010, Aardvark Therapeutics, Inc., as Director, Ignyta, Inc., as Chief Operating Officer from 2014 to 2018, Shire Pharmaceuticals, Inc., as Business Development Associate, Neurocrine Biosciences, Inc., as Senior Manager-Products from 2006 to 2008, Ignyta, Inc., as Chief Operating Officer & Vice President in 2018, and The Lek, as Life Sciences Consultant.
Mr. Hornby received his undergraduate degree in 2001 and graduate degree in 2001 from Stanford University and Masters Business Admin degree in 2006 from Harvard Business School.